Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or
 all-cause mortality in COPD patients who are new users of Olodaterol or other LABAs available
 for the treatment of COPD.
Purpose:

 Time Perspective:
Inclusion criteria:

 -  COPD diagnosis

 -  aged 40 years or older (to minimise the likelihood of including individuals who have
 asthma only)

 -  New user of olodaterol or a new user of indacaterol, salmeterol, or formoterol (not in
 fixed-dose combination with an inhaled corticosteroid) and have no dispensing of any
 LABA in the 6 months before the index date

 -  at least 1 year of enrolment in the electronic database before their first LABA
 dispensing (defined as the index LABA)

 -  Complete data on sex

 Exclusion criteria:

 none